Timing of erythropoietin modified mesenchymal stromal cell transplantation for the treatment of experimental bronchopulmonary dysplasia.
J Cell Mol Med
; 22(11): 5759-5763, 2018 11.
Article
en En
| MEDLINE
| ID: mdl-30160360
ABSTRACT
The aim of this study is to optimize the timing of erythropoietin gene modified mesenchymal stem cells (EPO-MSCs) transplantation for bronchopulmonary dysplasia (BPD). Three weeks post-operation, the results indicated that the damage of airway structure and apoptosis were significantly decreased, the proliferation was increased in three EPO-MSCs transplantation groups as compared with BPD mice. Moreover, the inflammation cytokines were improvement in early EPO-MSCs injection mice than in BPD mice, but there was no significant difference between late injection and BPD groups. Furthermore, the protein expression ratio of p-p38/p38MAPK was down-regulation in early mice but not in late transplantation mice. Our findings suggest that EPO-MSCs maybe attenuate BPD injury in early than in late administration by inhibiting inflammation response through down-regulation of the p38MAPK signalling pathway.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Displasia Broncopulmonar
/
Eritropoyetina
/
Trasplante de Células Madre Mesenquimatosas
/
Proteínas Quinasas p38 Activadas por Mitógenos
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
/
Newborn
Idioma:
En
Año:
2018
Tipo del documento:
Article